Back to results
US 7,888,000 B2Granted
Method for identifying salt-sensitive persons
AssigneeMorehouse School of Medicine
InventorsMyrtle Thierry-Palmer, Akins Doherty, Keri J. Griffin, Mohamed A. Bayorh
Life of this patent
Estimating the term…
Abstract
Salt sensitivity is measured as a function of the urinary 25-OHD binding activity, which may be evaluated by measuring 25-hydroxyvitamin D binding activity using radiolabeled 25-hydroxyvitamin D3. High binding activity is indicative of salt sensitivity and is an important predictor for development of salt-sensitivity related hypertension.
Claims3
A method for determining salt sensitivity in an individual comprising:
- (1) adding a known amount of radiolabeled 25-hydroxyvitamin D3 to a first aliquot of a urine sample from an individual and to a second aliquot of the same urine sample, and adding a known amount of unlabeled 25-hydroxyvitamin D3 to the first aliquot;
- (2) incubating the first and the second aliquots prepared in step (1) to allow radiolabeled 25-hydroxyvitamin D3 binding to proteins in the urine;
- (3) precipitating the unbound radio labeled 25-hydroxyvitamin D3;
- (4) measuring the radioactivity in the supernatant of each aliquot of step (3);
- (5) comparing the radioactivity in the first aliquot with the radioactivity in the second aliquot, wherein an excess of radioactivity in the second aliquot over the radioactivity in the first aliquot is deemed indicative of 25-hydroxyvitamin D3 binding activity in the urine sample,
- wherein a higher-than-normal 25-hydroxyvitamin D3 binding activity in the urine is indicative of salt sensitivity or predisposition to salt-associated hypertension.
3 more elements
A method of determining specific 25-hydroxyvitamin D3 binding activity in a urine sample comprising the steps of:
- (1) adding a known amount of radiolabeled 25-hydroxyvitamin D3 to two or more identical samples of urine from an individual and a known amount of excess unlabeled 25-hydroxyvitamin D3 to half of the samples to compete with the radiolabeled 25-hydroxyvitamin D3 for binding proteins in the urine;
- (2) incubating all samples prepared in step (1) to allow radiolabeled 25-hydroxyvitamin D3 binding to proteins in the urine;
- (3) incubating samples prepared in step (2) in buffered dextran-coated charcoal, then centrifuging to precipitate the unbound radio labeled 25-hydroxyvitamin D3;
- (4) measuring the average radioactivity in the supernatant of each sample of step (3);
- (5) comparing the average radioactivity in the samples containing excess unlabeled 25-hydroxyvitamin D3 with those to which no unlabeled 25-hydroxyvitamin D3 had been added to determine 25-hydroxyvitamin D binding proteins in the urine sample, wherein an excess of average radioactivity in the samples which lacked unlabeled 25-hydroxyvitamin D3, over the average radioactivity of samples which contain excess unlabeled 25-hydroxy vitamin D3 is deemed indicative of 25-hydroxyvitamin D3 binding activity in the urine sample,
- wherein a higher-than-normal 25-hydroxyvitamin D3 binding activity in the urine is deemed indicative of salt sensitivity or predisposition to salt-associated hypertension.
3 more elements
Dependencies are inferred from the claim text.